{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:32:58Z","timestamp":1770453178444,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.msard.2018.12.005","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T02:36:41Z","timestamp":1543804601000},"page":"406-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4799-7579","authenticated-orcid":false,"given":"Carmen","family":"Alcal\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pz\u00e9re-Miralles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Evole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Estutia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gil-Perot\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.12.005_bib0001","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1212\/WNL.0000000000003694","article-title":"Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab","volume":"88","author":"Barton","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.12.005_bib0002","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.msard.2018.12.005_bib0003","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.msard.2018.12.005_bib0004","author":"Ghodasara"},{"key":"10.1016\/j.msard.2018.12.005_bib0005","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/jamadermatol.2014.1544","article-title":"Alopecia universalis successfully treated with adalimumab","volume":"150","author":"Gorcey","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.msard.2018.12.005_bib0006","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/TCRM.S134398","article-title":"Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis","volume":"13","author":"Guarnera","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.msard.2018.12.005_bib0007","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1474-4422(16)30382-9","article-title":"Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy","volume":"16","author":"Haghikia","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.12.005_bib0008","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","article-title":"The autoimmune basis of alopecia areata: a comprehensive review","volume":"14","author":"Islam","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2018.12.005_bib0009","first-page":"e404","article-title":"Alopecia areata. Current situation and perspectives","volume":"115","author":"Ju\u00e1rez-Rend\u00f3n","year":"2017","journal-title":"Arch. Argent. Pediatr."},{"key":"10.1016\/j.msard.2018.12.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a013615","article-title":"An overview of alopecias","volume":"4","author":"Qi","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.msard.2018.12.005_bib0011","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjd.14497","article-title":"Alopecia areata and health-related quality of life: a systematic review and meta-analysis","volume":"175","author":"Rencz","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.msard.2018.12.005_bib0012","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000354767","article-title":"Diphenylcyclopropenone-induced vitiligo in a patient with alopecia universalis","volume":"5","author":"Riad","year":"2013","journal-title":"Case Rep. Dermatol."},{"key":"10.1016\/j.msard.2018.12.005_bib0013","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fendo.2017.00254","article-title":"Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-tsh-receptor immune response","volume":"8","author":"Rotondi","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.msard.2018.12.005_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.msard.2018.12.005_bib0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","article-title":"Alopecia areata","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.msard.2018.12.005_bib0016","doi-asserted-by":"crossref","first-page":"148","DOI":"10.14310\/horm.2002.1501","article-title":"Graves\u2019 disease after treatment with alemtuzumab for multiple sclerosis","volume":"14","author":"Tsourdi","year":"2002","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.msard.2018.12.005_bib0017","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1352458515614092","article-title":"Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort","volume":"22","author":"Willis","year":"2016","journal-title":"Mult. Scler J."},{"key":"10.1016\/j.msard.2018.12.005_bib0018","first-page":"377","article-title":"The diagnosis and treatment of hair and scalp diseases","volume":"113","author":"Wolff","year":"2016","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.msard.2018.12.005_bib0019","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1756285617722706","article-title":"Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world","volume":"10","author":"Ziemssen","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2018.12.005_bib0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fneur.2017.00569","article-title":"Alopecia Universalis following Alemtuzumab treatment in multiple sclerosis: a barely recognized manifestation of secondary autoimmunity-report of a case and review of the literature","volume":"8","author":"Zimmermann","year":"2017","journal-title":"Front. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:44:00Z","timestamp":1761900240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818305339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":20,"alternative-id":["S2211034818305339"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.005","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}